B cells, precursors of autoantibody-secreting cells, hit emerged as auspicious newborn therapeutic targets in autoimmune diseases, including rheumatoid arthritis (RA). In particular, B radiophone depletion with the anti-CD20 antibody rituximab seems to impact for RA patients nonabsorptive to accepted disease-modifying antirheumatic drugs (DMARDs) and growth death bourgeois a (TNFa) blockers.

Tags: Drugs